Biogen (BIIB) return on equity (ROE)

Return on equity · fiscal 2025
7.1%

Biogen (BIIB) earned a return on equity of 7.1% in fiscal 2025 (the year ended December 31, 2025). That is 2.7 percentage points lower than the 9.8% of fiscal 2024. Figures as of 17 Nov 2026, 22:20 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Return on equity, fiscal 2025
7.1%
Change on fiscal 2024
−2.7 pts
Highest on record
44.1%fiscal 2019
Lowest on record
7.1%fiscal 2025
Fiscal years on record
192007–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Biogen return on equity (ROE), in more detail

Across the 19 fiscal years on record (2007–2025), the highest was 44.1% in fiscal 2019 and the lowest 7.1% in fiscal 2025. The fiscal 2025 figure is no higher than in any of the 18 earlier fiscal years on record, whose median is 20.0%.

History · 19 fiscal years

Return on equity by fiscal year

Biogen return on equity (ROE), year by year

Biogen (BIIB) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
20257.1% 2.7 pts down
20249.8% 1.9 pts up
20237.8% 14.9 pts down
202222.7% 8.5 pts up
202114.3% 23.1 pts down
202037.4% 6.7 pts down
201944.1% 10.2 pts up
201834.0% 13.8 pts up
201720.1% 10.4 pts down
201630.5% 7.3 pts down
201537.8% 10.7 pts up
201427.2% 5.5 pts up
201321.6% 1.8 pts up
201219.8% 0.6 pts up
201119.2% 0.6 pts up
201018.6% 3.0 pts up
200915.6% 2.1 pts up
200813.5% 2.0 pts up
200711.5%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

Return on equity at health care companies of similar size

Return on equity of Biogen and comparable companies
CompanyReturn on equityFiscal year
Royalty Pharma RPRX11.9%2025
Biogen BIIB7.1%2025
GE HealthCare Technologies GEHC20.1%2025
Alcon ALC4.4%2025
Mettler-Toledo International MTD3519.1%2022
Centene CNC-33.4%2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on BIIB

Biogen, figure by figure

Biogen (BIIB) overview: price, valuation and scorecardAll health care companies by market value

Biogen return on equity (ROE): questions and answers

What is Biogen's return on equity?

Biogen (BIIB) earned a return on equity of 7.1% in fiscal 2025 (the year ended December 31, 2025). That is 2.7 percentage points lower than the 9.8% of fiscal 2024.

Is Biogen's return on equity high or low compared with its own history?

The fiscal 2025 figure is no higher than in any of the 18 earlier fiscal years on record, whose median is 20.0%.

What are the highest and lowest return on equity figures on record for Biogen?

Across the 19 fiscal years on record (2007–2025), the highest was 44.1% in fiscal 2019 and the lowest 7.1% in fiscal 2025.

How is Biogen's return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Biogen (BIIB) return on equity (ROE)”, data as of 17 November 2026. https://funkfolio.com/stock/BIIB/roe

Underlying data: the company's filings with the SEC and Yahoo Finance.